The emerging class of GLP-1 receptor agonist and GIP combined medications, such as tirzepatide, semaglutide, and the recently introduced retatrutide, offer promising improvements in diabetes control. https://peptidescience088732.healthlineblog.com/48118/retatrutide-one-comparative-examination